| Bioactivity | FTX-6058 is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia[1][2]. | ||||||||||||
| Invitro | FTX-6058 inhibits PRC2 via binding to EED, which induces robust HbF protein expression in both cell and murine models[2]. | ||||||||||||
| Name | FTX-6058 | ||||||||||||
| CAS | 2490676-18-9 | ||||||||||||
| Formula | C22H18FN5O2 | ||||||||||||
| Molar Mass | 403.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Boerner LK. Virtual meeting delivers first time drug structures. April 12, 2021. [2]. Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference. |
FTX-6058
CAS: 2490676-18-9 F: C22H18FN5O2 W: 403.41
FTX-6058 is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 can induce HbF protei
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.